<DOC>
	<DOCNO>NCT01496807</DOCNO>
	<brief_summary>The purpose study see much drug Yervoy safely tolerate give people also receive drug call Sylatron . Investigators also wish find whether addition Yervoy increase chance Sylatron cause rise level antibody patient 's blood recognize tissue , know `` autoimmune '' antibody . Investigators also want find likely tumor shrink .</brief_summary>
	<brief_title>Yervoy With Sylatron Unresectable Stage 3 4 Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Must cytologically histologicallyconfirmed unresectable melanoma , previously untreated systemically BRAF inhibitor metastatic disease , meet one follow American Joint Committee Cancer ( AJCC ) stag criterion : AJCC Stage IV ( Tany , Nany , M1 ) ; AJCC Stage IIIB/C patient unresectable nodal/locoregional involvement ; Patients cutaneous , ocular mucosal melanoma eligible Must adequate hepatic , renal bone marrow function define follow parameter obtain within 4 week prior initiation study treatment . Hematologic Criteria : white blood count ( WBC ) &gt; /= 3.0 x 10^9/L , Platelet &gt; 100 x 10^9/L , Hemoglobin &gt; /= 9 g/dL 5.6 mmol/L ; Renal Hepatic Functional Criteria : Serum creatinine &lt; 2.0 mg/dL &lt; 140 Î¼mol/L , serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) &lt; 2 time upper normal limit laboratory normal ( ULN ) Must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Must give informed consent accord institutional policy Must willing give write informed consent must able adhere dose visit schedule Female patient childbearing potential must use medically accept method birth control prior Screening agree continue use study surgically sterilize ( eg , hysterectomy tubal ligation ) . Females childbearing potential counseled appropriate use birth control study . Females currently sexually active must agree consent use one abovementioned method become sexually active participate study . Female patient childbearing potential must negative serum pregnancy test ( betahCG ) Screening . Female patient pregnant , intend become pregnant , nurse Previously treat interferon alpha 2b , Sylatron Yervoy therapy melanoma Patients whose disease completely surgically resect Have recover effect recent surgery Patients history prior malignancy within past 2 year surgically cure squamous basal cell carcinoma skin , cervical carcinoma situ Have severe cardiovascular disease , ie . arrhythmias require chronic treatment , congestive heart failure ( NYHA Class III IV ) symptomatic ischemic heart disease Patients thyroid dysfunction responsive therapy Patients , opinion investigator , uncontrolled diabetes mellitus Suffering active autoimmune disease except medically control hypothyroidism vitiligo An active and/or uncontrolled infection , include active hepatitis Have history seropositivity HIV Preexisting psychiatric condition , include limited : History severe depression ( include Hospitalization depression , Electroconvulsive therapy depression , Depression result prolonged absence work and/or significant disruption daily function ) ; Suicidal homicidal ideation and/or suicidal homicidal attempt ; History severe psychiatric disorder ( eg , psychosis , posttraumatic stress disorder mania ) ; Past history current use lithium and/or antipsychotic drug A clinical diagnosis substance abuse one follow drug , within follow timeframes , ( include time spent detoxification , hospitalization incarceration ) : Alcohol , intravenous drug use ( IVDU ) , inhalational , psychotropics , narcotic , cocaine , prescription overthecounter drug : within 1 year Screening visit ; Receiving methadone , buprenorphine hydrochloride ( HCL ) , and/or butorphanol tartrate within 1 year Screening visit , unless participant drug screen negative ( nonnarcotic ) drug document past year repeat negative within 2 month Screening visit ; Multidrug abuse ( 2 substance 17a 17b ) within 3 year Screening visit ; If patient 's historic marijuana use deem excessive principal investigator ( PI ) , medically qualify individual interfering patient 's life , patient eligible screen . If patient 's marijuana use deem excessive PI interfere life , patient must instruct discontinue current use recreational marijuana prior entry study . Patients medical condition require chronic systemic corticosteroid Known allergic drug substance excipients Sylatron Yervoy formulation Patients situation condition , opinion investigator , may interfere optimal participation study Have use investigational drug within 30 day study entry Are participate clinical treatment study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>unresectable</keyword>
	<keyword>stage 3</keyword>
	<keyword>stage 4</keyword>
	<keyword>autoimmune</keyword>
	<keyword>antibody</keyword>
</DOC>